Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease
| Autor: | Hidehiko Nakamura, Naoki Nishiyama, Shiro Nakahara, Sayuki Kobayashi, Kota Yamada, Isao Taguchi, Akinori Fujikake, Sachiko Komatsu, Takanori Kuroyanagi, Takaaki Komatsu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Paclitaxel medicine.medical_treatment Coronary Artery Disease 030204 cardiovascular system & hematology Balloon Coronary Angiography Coronary artery disease Coronary Restenosis 03 medical and health sciences 0302 clinical medicine Restenosis Angioplasty Internal medicine Medicine Humans cardiovascular diseases 030212 general & internal medicine Angioplasty Balloon Coronary Aged business.industry Stent Percutaneous coronary intervention Drug-Eluting Stents Middle Aged medicine.disease Antineoplastic Agents Phytogenic Coronary Vessels Surgery surgical procedures operative Treatment Outcome Drug-eluting stent Conventional PCI Cardiology Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | International journal of cardiology. 222 |
| ISSN: | 1874-1754 |
| Popis: | Despite the low restenosis rates of drug-eluting stents (DES), several problems remain, including stent thrombosis, stent fracture, and neo-atherosclerosis. 'Stent-less' (balloon alone) percutaneous coronary intervention (PCI) is still being used, and several clinical trials have supported the efficacy of DCB. The aim of this study was to investigate the efficacy of a drug-coated balloon (DCB) in the treatment of de novo coronary artery disease.We enrolled 60 consecutive patients who had been given elective PCI between May 2014 and June 2015. They were randomly assigned to a 'stent-less' group (n=30) and a 'stent' group (n=30). Twenty-seven patients were treated with DCB alone and 33 with DES, and then evaluated for target lesion revascularization (TLR) rate and by quantitative coronary angiography (QCA) eight months later.TLR rates were similar in the two groups (DCB; 0.0%, DES; 6.1%, P=0.169). In the QCA analysis, minimal lumen diameter (MLD) and acute gain were significantly smaller in the DCB group than in the DES group immediately after PCI (2.36±0.46 vs 2.64±0.37, P=0.011, and 1.63±0.41 vs 2.08±0.37, P0.0001, respectively). Eight months after PCI, however, there was no significant difference in MLD or late lumen loss between the two groups.A 'stent-less' PCI using DCB could be useful even in the DES era. After 'stent-less' PCI, antiplatelet agents might be reduced or discontinued more safely than after DES implantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect